380 related articles for article (PubMed ID: 7627336)
1. Technetium-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitary adenomas.
Lastoria S; Colao A; Vergara E; Ferone D; Varrella P; Merola B; Lombardi G; Salvatore M
Eur J Endocrinol; 1995 Jul; 133(1):38-47. PubMed ID: 7627336
[TBL] [Abstract][Full Text] [Related]
2. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.
Colao A; Ferone D; Lombardi G; Lastoria S
Clin Endocrinol (Oxf); 2002 Jun; 56(6):713-21. PubMed ID: 12072040
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of pituitary adenomas from other sellar and parasellar tumors by 99mTc(V)-DMSA scintigraphy.
Yamamura K; Suzuki S; Yamamoto I
Neurol Med Chir (Tokyo); 2003 Apr; 43(4):181-6; discussion 187. PubMed ID: 12760496
[TBL] [Abstract][Full Text] [Related]
4. Impaired growth hormone secretion in patients operated for pituitary adenomas.
Hoeck HC; Bang F; Laurberg P
Growth Regul; 1994 Jun; 4(2):63-7. PubMed ID: 7950904
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas.
Vukomanovic VR; Matovic M; Doknic M; Ignjatovic V; Simic Vukomanovic I; Djukic S; Peulic M; Djukic A
Nucl Med Commun; 2019 Jan; 40(1):41-51. PubMed ID: 30334858
[TBL] [Abstract][Full Text] [Related]
6. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
8. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
9. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
[TBL] [Abstract][Full Text] [Related]
11. Technetium-99m-pentavalent dimercaptosuccinic acid uptake in Hurthle cell tumor of the thyroid.
Vergara E; Lastoria S; Varrella P; Lapenta L; Salvatore M
J Nucl Biol Med (1991); 1993 Jun; 37(2):65-8. PubMed ID: 8396979
[TBL] [Abstract][Full Text] [Related]
12. Follicle-stimulating hormone-secreting pituitary adenomas.
Beckers A; Stevenaert A; Mashiter K; Hennen G
J Clin Endocrinol Metab; 1985 Sep; 61(3):525-8. PubMed ID: 2991325
[TBL] [Abstract][Full Text] [Related]
13. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas.
Arafah BM
J Clin Endocrinol Metab; 1986 Jun; 62(6):1173-9. PubMed ID: 3009521
[TBL] [Abstract][Full Text] [Related]
14. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Management of Cosecreting Thyroid Stimulating Hormone or Prolactin Pituitary Growth Hormone Adenomas: A Case-Control Study.
Mo C; Chen H; Xu J; Guo Y; Wang Y; Li Z; Tong T; Gui S; Zhong L
Endocr Pract; 2024 May; 30(5):441-449. PubMed ID: 38307455
[TBL] [Abstract][Full Text] [Related]
16. Relationship between plasma prolactin concentration and pituitary function in patients with a pituitary adenoma.
Hagen C; Lindholm J; Suenson E; Riishede J; Hummer L; Jacobsen HH
Clin Endocrinol (Oxf); 1979 Dec; 11(6):671-9. PubMed ID: 231491
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
18. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid.
Ugur O; Kostakğlu L; Güler N; Caner B; Uysal U; Elahi N; Haliloğlu M; Yüksel D; Aras T; Bayhan H; Bekdik C
Eur J Nucl Med; 1996 Oct; 23(10):1367-71. PubMed ID: 8781142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
